Key result
Body surface mapping demonstrated that maximum ST segment amplitudes at J0, J20, and J60 were significantly larger in patients with symptomatic Brugada syndrome compared to asymptomatic patients.
Why the study?
Does body surface mapping differentiate patients with Brugada syndrome from patients with asymptomatic Brugada syndrome?
Cross-Sectional (n=42)
No
Does body surface mapping differentiate patients with Brugada syndrome from patients with asymptomatic Brugada syndrome?
Answers are grounded in this paper and cite their sources.
Body surface mapping, both at baseline and following Ic antiarrhythmic drug challenge, is a useful non-invasive tool to differentiate symptomatic from asymptomatic Brugada syndrome patients.
We attempted to determine the usefulness of body surface mapping (BSM) for differentiating patients with Brugada syndrome (BS) from patients with asymptomatic Brugada syndrome (ABS). Electrocardiograms (ECG) and BSM were recorded in 7 patients with BS and 35 patients with ABS. Following the administration of Ic antiarrhythmic drugs, BSM was recorded in 5 patients with BS and 16 patients with ABS. The maximum amplitudes at J0, J20, J40 and J60 were compared between the 2 groups, as were 3-dimensional maps. The maximum amplitudes at J0, J20 and J60 under control conditions were larger in patients with BS than in patients with ABS (P < 0.05). A three-dimensional map of the ST segments under control conditions in patients with BS showed a higher peak of ST elevation in the median precordium compared to that for patients with ABS. Increases in ST elevation at J20, J40 and J60 following drug administration were greater in patients with BS than in patients with ABS (P < 0.05). Evaluation of the change in amplitude of the ST segment at E5 caused by Ic drug administration was also useful for differentiating between the 2 groups. In conclusion, BSM was useful for differentiating patients with BS from those with ABS.
No takes yet. Share an insight, caveat, or question.
Hisamatsu et al. (2004) conducted a cross-sectional in Brugada syndrome (n=42). Body surface mapping (BSM) with pilsicainide challenge vs. Asymptomatic Brugada syndrome patients was evaluated on Maximum ST segment amplitude at J20 under control conditions (mV) (p=<0.05). Body surface mapping demonstrated that maximum ST segment amplitudes at J0, J20, and J60 were significantly larger in patients with symptomatic Brugada syndrome compared to asymptomatic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: